Geron (GERN) Other Non-Current Assets (2010 - 2026)
Geron (GERN) posted Other Non-Current Assets of $5.9 million for Q1 2026, little changed sequentially from $5.9 million in Q4 2025, and up 47.31% YoY from $4.0 million in Q1 2025.
Geron (GERN) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Geron has reported Other Non-Current Assets for 14 years, with the latest figure at $5.9 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 47.31% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 47.31% YoY) and the FY2025 annual result came in at $5.9 million, up 45.75% from the prior year.
- Other Non-Current Assets was little changed at $5.9 million in Q1 2026 per GERN's latest filing, from $5.9 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $6.3 million in Q1 2022 and troughed at $2.7 million in Q3 2025.
- A 5-year average of $4.8 million and a median of $4.7 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets surged 48.01% in 2022, then slumped 45.95% in 2025.
- Over 5 years, Other Non-Current Assets stood at $5.4 million in 2022, then declined by 12.84% to $4.7 million in 2023, then decreased by 13.16% to $4.1 million in 2024, then jumped by 45.75% to $5.9 million in 2025, then dropped by 0.02% to $5.9 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $5.9 million, $5.9 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 5.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.70 Mn |
| Mar 31, 2026 | 5.94 Mn |
| Dec 31, 2025 | 5.95 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 3.15 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.74 Mn |
| Mar 31, 2024 | 4.71 Mn |
| Dec 31, 2023 | 4.70 Mn |
| Sep 30, 2023 | 5.20 Mn |
| Jun 30, 2023 | 4.75 Mn |
| Mar 31, 2023 | 4.69 Mn |
| Dec 31, 2022 | 5.39 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Jun 30, 2022 | 5.70 Mn |
| Mar 31, 2022 | 6.32 Mn |
| Dec 31, 2021 | 4.80 Mn |
| Sep 30, 2021 | 4.88 Mn |